AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06339320 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Description: The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
Study NCT06339320 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo OverStitch endoscopic suturing device
Description: Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
Study NCT05720442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangweian Recipe
Description: The Tangweian recipe is a combination of several Chinese herbs
Study NCT05720442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate
Description: The mosapride citrate tablets will be administrated.
Study NCT05720442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate
Description: The mosapride citrate tablets will be administrated.
Study NCT05796804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOR SPINAE PLANE BLOCK
Description: ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
Study NCT05796804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peng block + lateral femoral cutaneous nerve block
Description: ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
Study NCT05796804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.5% 2.2 ml
Study NCT05776914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Fecal Microbiota Transplantation
Description: Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
Study NCT05776914 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fecal Microbiota Transplantation
Description: Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
Study NCT06614036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
Study NCT04861558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Injection of 250-850 mg/m2.
Study NCT04861558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Injection of 360 mg/m2
Study NCT04861558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Injection of 460 mg/m2
Study NCT05356741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-818
Description: Administered as IV infusion
Study NCT05356741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as IV infusion
Study NCT04190212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training + standard care
Description: HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
Study NCT05043246 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: the antibody titer and adverse reactions were observed.
Study NCT06614036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
Study NCT04865185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine spray 100mg/ml
Description: Topical application
Study NCT04865185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Topical application
Study NCT04705441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART 2
Description: Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
Study NCT04934306 — intervention group
Intervention type: OTHER
Intervention: Nasometry
Description: Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
Study NCT05969275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived human mesenchymal stromal cells
Description: Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
Study NCT05969275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo, with excipients
Study NCT06554756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva, serum and GCF sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
Study NCT06554756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva, serum and GCF sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
Study NCT04652284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: 150 mg
Study NCT04652284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1000 mg
Study NCT06547918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 SA2.0 System
Description: The Omnipod 5 SA2.0 System provides automated insulin delivery based on Continuous Glucose Monitoring (CGM) values.
Study NCT04868370 — intervention group
Intervention type: OTHER
Intervention: Assessment of the upper limb (VPIT + PPIT)
Description: Assessment of the upper limb sensorimotor function (VPIT and PPIT)
Study NCT06197542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
Study NCT06197542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
Study NCT06619821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
Study NCT05498818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell
Description: 7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
Study NCT05498818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Study NCT06619821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCE promotion
Description: The intervention requires parents to complete a weekly parent-child interaction task designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
Study NCT06619821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study NCT04652284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40 mg
Study NCT04652284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500 mg
Study NCT04652284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: 500 mg
Study NCT06411340 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT05943119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy in painting dose on histoscannographic mapping
Description: The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone).
Study NCT05943119 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard pan-sinusal Radiotherapy
Description: The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone).
Study NCT06619821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study NCT06619899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAP exercise with 0% body mass
Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.
Study NCT06619899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAP exercise with 20% body mass
Description: Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass
Study NCT06619899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No PAP exercise
Description: No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.
Study NCT06691126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Terpinolene in olive oil
Description: Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
Study NCT04504708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
Study NCT06715345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone graft materials and rhBMP-2
Description: NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
Study NCT06716164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
Study NCT06719479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAE0972+ Methotrexate
Description: IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Methotrexate is used according to the instructions.
Study NCT06719479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAE0972+Docetaxel
Description: IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Docetaxel is used according to the instructions.
Study NCT06719479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAE0972+Gemcitabine
Description: IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Gemcitabine is used according to the instructions.
Study NCT06719479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAE0972+Taxanes
Description: IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Taxanes is used according to the instructions.
Study NCT06719479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAE0972+Capecitabine
Description: IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Capecitabine is used according to the instructions.
Study NCT06708338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle bevel orientation for arteriovenous fistula puncture
Description: For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group
Study NCT06708338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle bevel orientation for arteriovenous fistula puncture
Description: For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group
Study NCT06718738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM96 CAR-T Cells
Description: IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
Study NCT06718231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical acupoint stimulation
Description: After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints, and sham acupoints. The target treatment acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery.
Study NCT06718231 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-TAES
Description: After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral sham acupoints. The Sham acupoints is 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints. The sham acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery
Study NCT05833906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 1
Description: Subjects will be administered 5 g of CKR-051.
Study NCT05833906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 2
Description: Subjects will be administered 10 g of CKR-051.
Study NCT03662633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast cancer group
Description: All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study NCT03662633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Benign breast tumor group
Description: All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study NCT05833906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 3
Description: Subjects will be administered 10 g of CKR-051.